(RTTNews) - Daiichi Sankyo Company, Limited (4568.T) announced that Japan's Ministry of Health, Labour and Welfare has approved Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan) for new first-line indications in metastatic breast cancer.